Biotech Values

[oc631]

ABT-450 has six all-oral trials in phase-3, while Simeprevir has zero all-oral trials in phase-3; that’s a pretty big distinction.

I see more potential in simeprevir. The drug should have a 2-year approval lead (over GILD and ABBV) in GT1 primary markets and can establish itself as a best choice regime in secondary markets through pricing. JNJ/Medivir is also seeking GT4 labeling for simeprevir in Europe. JNJ/Medivir could license IDX-719 for oral use so there are potential binary events here that could impact the price of Medivir stock. A P.I./NS5A oral combo, if viable, would be a differentiated offering. Right now simeprevir is a stand alone, interferon-based option whereas ABT-450 is just an important ingredient within a multi-drug oral combo.